Clinical Edge
Executive Summary
Brief summaries of recent advances in device research and clinical trials, including an implantable sensor designed to measure cancer progression and treatment, new findings on angiogenesis-suppressing genes that protect Down's syndrome patients from cancer, research that implacates two inflammation-related proteins in breast cancer outcomes, and stem-cell implanted contact lenses that repair corneal damage.
You may also be interested in...
Warning Confirms Some Supplement GMP Violations Remain Common In US
An Oregon factory’s citations received by the FDA are among the most common violations the agency finds during inspections, ORA Office of Human and Animal Food Operations deputy director said.
‘The Story That No One Likes To Hear’: Investors Looking For Surer Bets In Health Tech After Record 2021
A panel of investors and leaders in healtech expects investment in health tech to decline, but still foresees opportunities for companies working on solutions that will transform overall health care such as AI, ML, mental health and health equity.
Bluebird’s Zynteglo Launch Under Way, But First Revenue Will Take Months
Bluebird bio will not see revenue for Zynteglo until it is infused into beta-thalassemia patients, which will take months due to the ex vivo gene therapy’s complex manufacturing and quality control process.